Buy CJC-1295 (No DAC) + Ipamorelin Blend

Shop by goal

Popular compounds

BPC-157

Research resources

Compare pack sizes

Tap a pack to select it in the purchase panel above

Lab-direct quality — sealed 10-vial packs

Every batch ships straight from the lab that synthesises it — sealed, tamper-evident. Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a sealed 10-vial research pack in the strength your research needs.

Scientific Research Context

What the published literature on the components of CJC-1295 (No DAC) + Ipamorelin Blend examines. These are findings about each compound in the studies cited, not claims about the blend or the supplied material.

Ipamorelin: selective GH release

In rat pituitary cells, anaesthetised rats and conscious swine ipamorelin released growth hormone with a potency and efficacy comparable to GHRP-6. None of the secretagogues tested changed FSH, LH, prolactin or TSH. GHRP-6 and GHRP-2 raised ACTH and cortisol; ipamorelin did not, even above 200 times its GH-releasing ED50. [animal and in vitro]

Which receptor ipamorelin uses

Profiling with GHRP and GHRH antagonists indicated that ipamorelin, like GHRP-6, stimulates GH release through a GHRP-like receptor and not through the GHRH receptor, the receptor CJC-1295 targets. [in vitro and animal]

The DAC relative of CJC-1295 in healthy adults

CJC-1295 with DAC, a long-acting analogue and a different molecule from the no-DAC form supplied here, raised mean growth hormone 2- to 10-fold for six days or more and IGF-I 1.5- to 3-fold for 9-11 days in a randomised placebo-controlled study of healthy adults, with an estimated half-life of 5.8-8.1 days. [human, DAC form only]

Where the CJC-1295 chemistry comes from

The original characterisation of CJC-1295 describes GRF(1-29) analogues bioconjugated to albumin and their activation of the GRF receptor on rat anterior pituitary. It concerns the long-acting conjugate rather than the unconjugated no-DAC form. [animal]

Overview

In short: A fixed 1:1 research blend of CJC-1295 (no DAC) and ipamorelin, offered at 5 mg + 5 mg and 10 mg + 10 mg per vial: a growth-hormone-releasing-hormone analogue and a selective ghrelin-receptor agonist in one vial.

Key research facts

Two growth-hormone-axis research peptides pre-combined at a fixed 1:1 ratio

Two vial strengths in one product: 5 + 5 mg and 10 + 10 mg

CJC-1295 (no DAC): tetrasubstituted GHRH(1-29) analogue acting on the GHRH receptor

Ipamorelin: pentapeptide characterised as a selective growth hormone secretagogue

Two different receptors on the same cell type, the usual reason the pair is studied together

These points summarise lab themes, not human outcomes.

The two compounds reach the same pituitary cell type through different receptors, which is the whole case for studying them together. CJC-1295 without DAC (modified GRF(1-29)) is the first 29 residues of growth-hormone-releasing hormone with four substitutions that make it resistant to the enzymes that normally inactivate the native peptide, and it acts on the GHRH receptor. Ipamorelin, Aib-His-D-2Nal-D-Phe-Lys-NH2, was developed at Novo Nordisk and acts on a ghrelin-type receptor instead.

The ipamorelin paper is the useful reference for the second half of the pair. It reports that ipamorelin released growth hormone from rat pituitary cells with a potency and efficacy similar to GHRP-6, that antagonist profiling put its action at a GHRP-like receptor rather than the GHRH receptor, and that in conscious swine it did not raise ACTH or cortisol beyond the levels seen after GHRH stimulation, even at doses more than 200 times its GH-releasing ED50, where GHRP-6 and GHRP-2 did.

There is no study of this fixed blend cited here. The vial strengths differ only in quantity (CP10 is 5 mg of each compound, CP20 is 10 mg of each). Supplied as lyophilised powder for in-vitro and preclinical research only.

Research class: Fixed two-compound research blend

Components: CJC-1295 (no DAC) + Ipamorelin

Vial strengths: 10 mg, 20 mg per vial, chosen from the pack-size menu

Research focus: Pituitary growth hormone release through the GHRH receptor and the ghrelin-type receptor

Evidence base: Rat, pig and in-vitro data for ipamorelin; human data for the long-acting DAC relative of CJC-1295; none on this blend

Proposed Mechanism

The blend has no combined mechanism. CJC-1295 (no DAC) is a GHRH-receptor agonist and ipamorelin a ghrelin-type receptor agonist; both act on pituitary somatotrophs through different receptors. Pairing them is a hypothesis about those two routes, not a demonstrated property of the vial.

Pathway Effect Why it matters GHRH receptor (CJC-1295 no DAC) Tetrasubstituted GHRH(1-29) analogue designed to resist enzymatic inactivation One of the two receptors the pair is chosen to engage Ghrelin-type receptor (ipamorelin) Releases GH through a GHRP-like receptor, not the GHRH receptor The second route; the antagonist profiling in the ipamorelin paper supports the distinction ACTH and cortisol No rise beyond the GHRH-stimulated level for ipamorelin in swine, unlike GHRP-6 and GHRP-2 The selectivity result that made ipamorelin a research tool No shared pharmacology Each component retains its own published pharmacology Interpret results per component, not for the pair

Deeper dive for scientific readers

Two different receptors on the same pituitary cell is the textbook reason to study a GHRH analogue and a ghrelin-receptor agonist together, but this page does not cite a study of that pair as a fixed vial, and the only human data cited concern the DAC form, which is a different molecule. A fixed 1:1 vial also removes the ability to vary one compound against the other. Use the stand-alone CJC-1295 (no DAC) and ipamorelin products when a design needs that independence.

Common Questions People Are Asking

What is in the CJC-1295 (No DAC) + Ipamorelin Blend?

Each vial holds CJC-1295 without DAC and ipamorelin in a fixed 1:1 ratio: 5 mg of each (10 mg per vial, code CP10) or 10 mg of each (20 mg per vial, code CP20). Choose the strength from the pack-size menu.

Why are the two compounds paired?

They act on the same pituitary cell type through different receptors: CJC-1295 on the GHRH receptor and ipamorelin on a ghrelin-type receptor. That is the rationale for studying them together. This page cites no study of the fixed blend itself.

Is this the same as CJC-1295 with DAC?

No. The DAC form carries an albumin-binding group and acts for days; the no-DAC form in this vial does not. The human study in the references used the DAC form, so its results are not findings about this blend.

Is there a Certificate of Analysis for this blend?

Not yet. No independent analytical report has been published for this material, so no purity figure is quoted. If one is published it will appear on this page and on our COA page.

Is there human data on this blend?

No study of the blend is cited. This is laboratory research material, sold strictly for in-vitro and preclinical research and not for human or veterinary use.

Where can I buy CJC-1295 (No DAC) + Ipamorelin Blend?

Right here - CJC-1295 (No DAC) + Ipamorelin Blend is supplied directly by New-U Research Compounds on this page, as lyophilised research-grade material, and shipped direct from source worldwide in discreet, tracked packaging.

How much does CJC-1295 (No DAC) + Ipamorelin Blend cost?

CJC-1295 (No DAC) + Ipamorelin Blend pricing is shown live on this page, per pack size - 10-vial research packs as standard, with single-vial sample options on selected compounds. Larger vial strengths lower the per-mg cost, and shipping is free on orders over $350.

How do I buy CJC-1295 (No DAC) + Ipamorelin Blend?

Add the CJC-1295 (No DAC) + Ipamorelin Blend pack size you need to your cart and check out: enter your shipping details, then choose your payment method - cryptocurrency or card - on the next step.

What payment methods can I use to buy CJC-1295 (No DAC) + Ipamorelin Blend?

At checkout you can pay by card or crypto. New-U supports BTC and selected stablecoin and network-asset payments across Ethereum, Solana, TRON, Polygon, Base, BNB Chain and Linea. You choose your method after confirming your order.

How fast is shipping, and do you ship worldwide?

Yes - we ship worldwide in discreet, unmarked, tracked packaging; lyophilised peptides are stable through the tracked transit window. Delivery typically takes 6–14 business days, and shipping is free on orders over $350.

Is it legal to buy CJC-1295 (No DAC) + Ipamorelin Blend?

In the United States, CJC-1295 (No DAC) + Ipamorelin Blend is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Stability Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. Notes Laboratory research material. No amount, schedule or administration guidance is published or recommended on this page.

Evidence Tier

Overall: Tier 3: Limited / anecdotal

The blend has no evidence base of its own. Ipamorelin has animal and in-vitro pharmacology; the human CJC-1295 data concern the long-acting DAC conjugate, not the no-DAC form in this vial. No study of the two as a fixed combination is cited. The material is supplied as unapproved laboratory material.

Tier 1 · Human clinical

A randomised placebo-controlled study of the long-acting DAC form of CJC-1295 in healthy adults (not the form supplied here)

Tier 2 · Animal

Ipamorelin GH release and selectivity in rat pituitary cells, rats and swine

GRF(1-29) analogue and albumin-conjugate characterisation in rats

Databases & peer-reviewed sources

Last reviewed: 14 October 2026 · New-U Research Compounds

Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. · 1998 · PMID: 9849822 · DOI: 10.1530/eje.0.1390552

Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006. · 2006 · PMID: 16352683 · DOI: 10.1210/jc.2005-1536

Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005. · 2005 · PMID: 15817669 · DOI: 10.1210/en.2004-1286

PubMed: peer-reviewed literature on CJC-1295 + Ipamorelin Blend

ClinicalTrials.gov: registered studies on CJC-1295 + Ipamorelin Blend

CJC-1295 + Ipamorelin Blend: Wikipedia (search)

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

Fixed 1:1 blend of CJC-1295 (no DAC) and ipamorelin in every vial

Two strengths: 5 + 5 mg (CP10) and 10 + 10 mg (CP20)

CJC-1295 (no DAC): modified GRF(1-29), about 3,368 Da, GHRH-receptor agonist

Ipamorelin: Aib-His-D-2Nal-D-Phe-Lys-NH2, about 712 Da, ghrelin-type receptor agonist

Two receptors on the same pituitary cell type

No study of the fixed blend is cited; human data cited concern the DAC form only

No analytical report published yet; sold as a sealed 10-vial pack, one strength per pack

Specifications

Components CJC-1295 (no DAC) + Ipamorelin Vial CP10 CJC-1295 (no DAC) 5 mg + Ipamorelin 5 mg (10 mg per vial) Vial CP20 CJC-1295 (no DAC) 10 mg + Ipamorelin 10 mg (20 mg per vial) Pack 10 vials, one strength per pack Analytical report None published yet Form Lyophilised powder Storage Lyophilised: −20 °C freezer. Reconstituted: 1-6 °C, away from light.

About the CJC-1295 (No DAC) + Ipamorelin Blend: Research Guide

CJC-1295 without DAC and ipamorelin are two of the most commonly paired compounds in growth-hormone-axis research, one acting at the GHRH receptor and the other at a ghrelin-type receptor. Supplying them in one vial removes a weighing and reconstitution step for studies that call for a matched ratio.

The distinction between CJC-1295 with DAC and without it matters here. The DAC form carries a chemical group that binds albumin and extends its half-life from minutes to days; the no-DAC form supplied in this blend does not, and the human data in the references concern the DAC form. Nothing in this listing should be read across from one molecule to the other.

New-U Research Compounds supplies this blend as laboratory research material only. No analytical report for it has been published yet, so no purity figure is quoted. Nothing on this page is medical advice or a recommendation to use it in people or animals.

Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998.

Customer Reviews

No customer reviews yet - be the first to share your experience.

More in Stacks

Stacks BPC-157 + TB-500 Blend BPC-157 and TB-500 in one vial at a fixed 1:1 ratio, in four strengths from 2 mg + 2 mg to 15 mg + 15 mg per vial: the two most-cited tissue-repair research peptides, pre-combined. BPC-157 + TB-500 Blend →

Stacks Tesamorelin + Ipamorelin Blend Tesamorelin and ipamorelin in one vial, in three strengths: 5 mg + 5 mg, 10 mg + 4 mg and 10 mg + 5 mg per vial. A GHRH(1-44) analogue paired with a selective ghrelin-receptor agonist. Tesamorelin + Ipamorelin Blend →

Stacks Semax + Selank Blend Semax and Selank in one vial at a fixed 1:1 ratio, in two strengths: 5 mg + 5 mg and 10 mg + 10 mg per vial. Two heptapeptides developed at the same Moscow institute. Semax + Selank Blend →

Stacks Glow Glow is a three-compound research blend combining GHK-Cu, BPC-157 and TB-500 in a single vial - the copper-binding tripeptide paired with the two most-studied tissue-repair peptides. Glow →

Stacks Klow Klow is a four-compound research blend - the Glow trio of GHK-Cu, BPC-157 and TB-500 with KPV added, pairing matrix and repair signalling with the alpha-MSH anti-inflammatory fragment. Klow →

CJC-1295 (No DAC) + Ipamorelin Blend vs related Stacks compounds

Compound Price Purity spec COA CJC-1295 (No DAC) + Ipamorelin Blend from $180 Not published On request BPC-157 + TB-500 Blend from $140 Not published On request Tesamorelin + Ipamorelin Blend from $220 Not published On request

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on CJC-1295 (No DAC) + Ipamorelin Blend

Multi-Compound Blends research compounds

CJC-1295 (No DAC) + Ipamorelin Blend research guide

Research this compound

Research guide CJC-1295 (No DAC) + Ipamorelin Blend research guide The blend has no combined mechanism. Read the guide →

Part of the Growth hormone secretagogue research research area — explore related compounds, guides and sources.

From our community

What people say on Facebook

PRECISION. PURITY. PERFORMANCE.

Research peptides. Third-party Certificates of Analysis (Janoshik Analytical & Freedom Diagnostics) are published on the website. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research